Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing

Contributed by: Business Wire

Logo

Tags

Health

Infectious Diseases

Neurology

Manufacturing

Other Manufacturing

Pharmaceutical

Biotechnology

Lyric Bio

More Like This

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery

Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform

Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI

KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing

Business Wire associated0

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

PR Newswire associated0

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development